Target Uric Acid Level for Preventing Gout and Its Management

Target Uric Acid Levels

The European League Against Rheumatism recommends that the target serum uric acid (SUA) level for preventing gout should be maintained below 6 mg/dL (360 μmol/L) lifelong in most patients, with a lower target of less than 5 mg/dL (300 μmol/L) recommended for patients with severe gout until crystal dissolution occurs 1, 2, 3
SUA should be maintained below 6 mg/dL (360 μmol/L) for all patients on urate-lowering therapy (ULT), as this is below the saturation point for monosodium urate (MSU) crystals (6.8 mg/dL) and promotes crystal dissolution 4, 5
For patients with severe gout (tophi, chronic arthropathy, frequent attacks), a lower target of less than 5 mg/dL (300 μmol/L) is recommended to facilitate faster crystal dissolution until resolution of gout 4, 6
Long-term maintenance of SUA below 3 mg/dL is not recommended due to potential protective effects of uric acid against neurodegenerative diseases 5, 6

The European League Against Rheumatism recommends that urate-lowering therapy (ULT) should be considered and discussed with every patient with a definite diagnosis of gout from the first presentation, with clear indications including recurrent acute attacks 1, 7
ULT is also indicated for patients with tophi 8, urate arthropathy or radiographic changes of gout 8, renal stones 7, young age at onset (<40 years) 6, very high SUA level (>8.0 mg/dL; 480 mmol/L) 7, and comorbidities (renal impairment, hypertension, ischemic heart disease, heart failure) 7, 6

The European League Against Rheumatism recommends allopurinol as first-line ULT in patients with normal kidney function 4, 6
Allopurinol should be started at a low dose (100 mg/day) and increased by 100 mg increments every 2-4 weeks until the SUA target is reached 5, 6
If SUA target cannot be reached with appropriate allopurinol dose, switch to febuxostat or a uricosuric agent, or combine allopurinol with a uricosuric 4, 5

The European League Against Rheumatism recommends prophylaxis against flares during the first 6 months of ULT 1, 9, 3
Recommended prophylactic treatment is colchicine, 0.5-1 mg/day (reduced in renal impairment) 9

The European League Against Rheumatism recommends that SUA levels should be monitored regularly and maintained below target lifelong 8, 5
Following complete dissolution of MSU crystals, SUA should still be maintained below 6 mg/dL to prevent recurrence 5
Studies show approximately 40% of successfully treated patients experience recurrence of flares after ULT withdrawal 5

The European League Against Rheumatism recommends lifestyle modifications, including weight loss if appropriate 1, avoidance of alcohol, especially beer and spirits 1, avoidance of sugar-sweetened drinks and foods rich in fructose 1, and encouragement of low-fat dairy products 1
Regular exercise (avoiding strenuous exercise that may trigger flares) is also recommended 1